Malard F, Mohty M. Acute lymphoblastic leukaemia, lancet Lond. Engl. 2020;395:1146–62. https://doi.org/10.1016/S0140-6736(19)33018-1.

Article  CAS  Google Scholar 

Cordoba S, Onuoha S, Thomas S, Pignataro DS, Hough R, Ghorashian S, Vora A, Bonney D, Veys P, Rao K, Lucchini G, Chiesa R, Chu J, Clark L, Fung MM, Smith K, Peticone C, Al-Hajj M, Baldan V, Ferrari M, Srivastava S, Jha R, Arce Vargas F, Duffy K, Day W, Virgo P, Wheeler L, Hancock J, Farzaneh F, Domning S, Zhang Y, Khokhar NZ, Peddareddigari VGR, Wynn R, Pule M, Amrolia PJ. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial. Nat Med. 2021;27:1797–805. https://doi.org/10.1038/s41591-021-01497-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen S-S, Wu W-Z, Zhang Y-P, Huang W-J. Gene polymorphisms of SOCS1 and SOCS2 and acute lymphoblastic leukemia. Eur Rev Med Pharmacol Sci. 2020;24:5564–72. https://doi.org/10.26355/eurrev_202005_21342.

Article  PubMed  Google Scholar 

Witkowski MT, Dolgalev I, Evensen NA, Ma C, Chambers T, Roberts KG, Sreeram S, Dai Y, Tikhonova AN, Lasry A, Qu C, Pei D, Cheng C, Robbins GA, Pierro J, Selvaraj S, Mezzano V, Daves M, Lupo PJ, Scheurer ME, Loomis CA, Mullighan CG, Chen W, Rabin KR, Tsirigos A, Carroll WL, Aifantis I. Extensive remodeling of the immune microenvironment in B cell acute lymphoblastic leukemia. Cancer Cell. 2020;37:867–e88212. https://doi.org/10.1016/j.ccell.2020.04.015.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Belyea BC, Xu F, Pentz ES, Medrano S, Li M, Hu Y, Turner S, Legallo R, Jones CA, Tario JD, Liang P, Gross KW, Sequeira-Lopez MLS, Gomez RA. Identification of Renin progenitors in the mouse bone marrow that give rise to B-cell leukaemia. Nat Commun. 2014;5:3273. https://doi.org/10.1038/ncomms4273.

Article  CAS  PubMed  Google Scholar 

Li Y, Yang X, Sun Y, Li Z, Yang W, Ju B, Easton J, Pei D, Cheng C, Lee S, Pui C-H, Yu J, Chi H, Yang JJ. Impact of T-cell immunity on chemotherapy response in childhood acute lymphoblastic leukemia. Blood. 2022;140:1507–21. https://doi.org/10.1182/blood.2021014495.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Perez-Garcia A, Ambesi-Impiombato A, Hadler M, Rigo I, LeDuc CA, Kelly K, Jalas C, Paietta E, Racevskis J, Rowe JM, Tallman MS, Paganin M, Basso G, Tong W, Chung WK, Ferrando AA. Genetic loss of SH2B3 in acute lymphoblastic leukemia. Blood. 2013;122:2425–32. https://doi.org/10.1182/blood-2013-05-500850.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao L, Li S, Wei X, Qi X, Liu D, Liu L, Wen F, Zhang J-S, Wang F, Liu Z-L, Cao YJ. A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL. Blood. 2022;140:1790–802. https://doi.org/10.1182/blood.2022016243.

Article  CAS  PubMed  Google Scholar 

Plantinga TS, Petrulea MS, Oosting M, Joosten LAB, Piciu D, Smit JW, Netea-Maier RT, Georgescu CE. Association of NF-κB polymorphisms with clinical outcome of non-medullary thyroid carcinoma. Endocr Relat Cancer. 2017;24:307–18. https://doi.org/10.1530/ERC-17-0033.

Article  CAS  PubMed  Google Scholar 

Ho I-C, Tai T-S, Pai S-Y. GATA3 and the T-cell lineage: essential functions before and after T-helper-2-cell differentiation. Nat Rev Immunol. 2009;9:125–35. https://doi.org/10.1038/nri2476.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang H, Zhang H, Luan Y, Liu T, Yang W, Roberts KG, Qian M-X, Zhang B, Yang W, Perez-Andreu V, Xu J, Iyyanki S, Kuang D, Stasiak LA, Reshmi SC, Gastier-Foster J, Smith C, Pui C-H, Evans WE, Hunger SP, Platanias LC, Relling MV, Mullighan CG, Loh ML, Yue F, Yang JJ. Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation. Nat Genet. 2022;54:170–9. https://doi.org/10.1038/s41588-021-00993-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Butterbach K, Beckmann L, de Sanjosé S, Benavente Y, Becker N, Foretova L, Maynadie M, Cocco P, Staines A, Boffetta P, Brennan P, Nieters A. Association of JAK-STAT pathway related genes with lymphoma risk: results of a European case-control study (EpiLymph). Br J Haematol. 2011;153:318–33. https://doi.org/10.1111/j.1365-2141.2011.08632.x.

Article  CAS  PubMed  Google Scholar 

Gu C, Can C, Liu J, Wei Y, Yang X, Guo X, Wang R, Jia W, Liu W, Ma D. The genetic polymorphisms of immune-related genes contribute to the susceptibility and survival of lymphoma. Cancer Med. 2023. https://doi.org/10.1002/cam4.6131.

Article  PubMed  PubMed Central  Google Scholar 

Lindgren M, Samuelsson J, Nilsson L, Knutsen H, Ghanima W, Westin J, Johansson PL, Andréasson B. Genetic variation in IL28B (IFNL3) and response to interferon-alpha treatment in myeloproliferative neoplasms. Eur J Haematol. 2018;100:419–25. https://doi.org/10.1111/ejh.13034.

Article  CAS  PubMed  Google Scholar 

Serin I, Colak Y, Oyaci Y, Tuncel FC, Pehlivan M, Pehlivan S. Effect of interleukin-2 (IL-2) polymorphisms on multiple myeloma: IL-2RA rs2104286, IL-2 rs2069762 and rs2069763 polymorphisms. Cytokine. 2023;172:156401. https://doi.org/10.1016/j.cyto.2023.156401.

Article  CAS  PubMed  Google Scholar 

Kantarjian H, Thomas D, O’Brien S, Cortes J, Giles F, Jeha S, Bueso-Ramos CE, Pierce S, Shan J, Koller C, Beran M, Keating M, Freireich EJ. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101:2788–801. https://doi.org/10.1002/cncr.20668.

Article  CAS  PubMed  Google Scholar 

Akahoshi Y, Arai Y, Nishiwaki S, Tachibana T, Shinohara A, Doki N, Uchida N, Tanaka M, Kanda Y, Shiratori S, Ozawa Y, Shono K, Katayama Y, Tanaka J, Fukuda T, Atsuta Y, Kako S. Newly proposed threshold and validation of white blood cell count at diagnosis for Philadelphia chromosome-positive acute lymphoblastic leukemia: risk assessment of relapse in patients with negative minimal residual disease at transplantation-a report from the adult acute lymphoblastic leukemia working group of the JSTCT. Bone Marrow Transpl. 2021;56:2842–8. https://doi.org/10.1038/s41409-021-01422-7.

Article  CAS  Google Scholar 

Chen C, Song N, Dong Q, Sun X, Mulder HL, Easton J, Zhang J, Yasui Y, Bhatia S, Armstrong GT, Wang H, Ness KK, Hudson MM, Robison LL, Wang Z. Association of Single-Nucleotide variants in the human leukocyte antigen and other loci with childhood hodgkin lymphoma, JAMA Netw. Open. 2022;5:e2225647. https://doi.org/10.1001/jamanetworkopen.2022.25647.

Article  Google Scholar 

Perez-Andreu V, Roberts KG, Harvey RC, Yang W, Cheng C, Pei D, Xu H, Gastier-Foster J, Lim SEJY-S, Chen I-M, Fan Y, Devidas M, Borowitz MJ, Smith C, Neale G, Burchard EG, Torgerson DG, Klussmann FA, Villagran CRN, Winick NJ, Camitta BM, Raetz E, Wood B, Yue F, Carroll WL, Larsen E, Bowman WP, Loh ML, Dean M, Bhojwani D, Pui C-H, Evans WE, Relling MV, Hunger SP, Willman CL, Mullighan CG, Yang JJ. Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat Genet. 2013;45:1494–8. https://doi.org/10.1038/ng.2803.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dai Y-T, Zhang F, Fang H, Li J-F, Lu G, Jiang L, Chen B, Mao D-D, Liu Y-F, Wang J, Peng L-J, Feng C, Chen H-F, Mu J-X, Zhang Q-L, Wang H, Ariffin H, Moy T.A., Wang J.-H., Lou Y.-J., Chen S.-N., Wang Q., Liu H., Shan Z., Matsumura I, Miyazaki Y., Yasuda T., Dou L.-P., Yan X.-J., Yan J.-S., Yeoh A.E.-J., Wu D.-P., Kiyoi H., Hayakawa F., Jin J., Wang S.-Y., Sun X.-J., Mi J.-Q., Chen Z., Huang J.-Y., Chen S.-J. Transcriptome-wide subtyping of pediatric and adult T cell acute lymphoblastic leukemia in an international study of 707 cases. Proc Natl Acad Sci U S A. 2022;119:e2120787119. https://doi.org/10.1073/pnas.2120787119.

Article  PubMed  PubMed Central  Google Scholar 

Lan T, Li H, Zhang D, Xu L, Liu H, Hao X, Yan X, Liao H, Chen X, Xie K, Li J, Liao M, Huang J, Yuan K, Zeng Y, Wu H. KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3, mol. Cancer. 2019;18:186. https://doi.org/10.1186/s12943-019-1106-z.

Article  CAS  Google Scholar 

LncRNA GATA3-AS. 1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3 but stabilization of PD-L1 - PubMed. https://pubmed.ncbi.nlm.nih.gov/32687248/ (accessed July 28, 2023).

Egler RA, Burlingame SM, Nuchtern JG, Russell HV. Interleukin-6 and soluble interleukin-6 receptor levels as markers of disease extent and prognosis in neuroblastoma, clin. Cancer Res Off J Am Assoc Cancer Res. 2008;14:7028–34. https://doi.org/10.1158/1078-0432.CCR-07-5017.

Article  CAS  Google Scholar 

An intermediate-risk. multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification - PubMed. https://pubmed.ncbi.nlm.nih.gov/22072558/ (accessed July 28, 2023).

Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15:234–48. https://doi.org/10.1038/nrclinonc.2018.8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang X, Wang Y, Qu GAC, Chen J. Pan-Cancer analysis of PARP1 alterations as biomarkers in the prediction of immunotherapeutic effects and the association of its expression levels and immunotherapy signatures. Front Immunol. 2021;12:721030. https://doi.org/10.3389/fimmu.2021.721030.

Article